SynBioLab (Biotechnology) key facts
- Operator of synthetic biology research and development company created to develop the production technology of high-value-added compounds.
- It has raised $1.6M; the latest was Later Stage VC in Jul 2025.
- Notable investors include Changde Caixin Financial Holding, Huada GreenPine Angel Fund, Bangming Capital, Green Startups, Hainan Houshi Private Equity Fund Management — 8 tracked in total.
- Status: Privately Held (backing).
- ·Watch SynBioLab (Biotechnology): the Monday email on marks, rounds and moves
SynBioLab (Biotechnology) funding rounds
No funding rounds for SynBioLab (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
SynBioLab (Biotechnology) investors
8 investors are on record for SynBioLab (Biotechnology), including Changde Caixin Financial Holding, Huada GreenPine Angel Fund, Bangming Capital and Green Startups.
About SynBioLab (Biotechnology)
Operator of synthetic biology research and development company created to develop the production technology of high-value-added compounds. The company focuses on the biosynthesis of high-value-added plant-derived medicinal compounds, it uses synthetic biology methods to redesign microbial metabolism pathways and build biological cell factories to manufacture high-purity, low-cost, low-polluting, high -value-added drugs, helping its clients greatly reduce the length of the production cycle and the cost of plant-derived compounds in an environmentally friendly way.
- Sector
- Healthcare
- HQ
- Jiaxing, China
- Founded
- 2017
- Employees
- 13
- Website
- synbiolab.cn/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
SynBioLab (Biotechnology) doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.